Selecta Biosciences, Inc. (NASDAQ:SELB) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET

Company Participants

Carsten Brunn - President and Chief Executive Officer

Kevin Tan - Chief Financial Officer

Peter Traber - Chief Medical Officer

Takashi Kishimoto - Chief Scientific Officer

Conference Call Participants

Elizabeth Scott - SVB Securities

Rick Miller - Cantor Fitzgerald

Yun Zhong - BTIG

John Newman - Canaccord

Tiffany Marchell - William Blair

Boobalan Pachaiyappan - H.C. Wainwright

Uy Ear - Mizuho

Operator

Good morning, and welcome to the Selecta Biosciences Third Quarter 2022 Financial Results and Business Update Conference Call. [Operator Instructions] This call is being webcast live on the Investor and Media section of Selecta's website at www.selectabio.com and is being recorded.

For opening remarks, I would like to introduce you, Mr. Kevin Tan, Chief Financial Officer of Selecta. Please go ahead, sir.

Kevin Tan

Thank you, and good morning. Welcome to our third quarter 2022 financial results and business update conference call. The press release reporting our financial results is available in the Investors and Media section of Selecta's website, worldwide web selectabio.com, and our quarterly report on Form 10-Q for the quarter ended September 30, 2022, which we intend to file in the coming days with the Securities and Exchange Commission, or SEC. Joining me today are Carsten Brunn, President and Chief Executive Officer; Peter Traber, Chief Medical Officer; and Kei Kishimoto, Chief Scientific Officer.

During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our financial projections, and our future expectations, plans, partnerships and prospects. These statements are subject to various risks that are described in the filings made with the SEC, including our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, November 3, 2022. And Selecta disclaims any obligation to update such statements, except as required by law, even if management's views change.

I would now like to turn the call over to Carsten Brunn. Carsten?

Carsten Brunn

Thank you, Kevin. Good morning. I appreciate everyone taking the time to join us today. In the third quarter of 2022, we continued to make steady progress across the pipeline. And with an expected financial runway into mid-2024, we believe we're well positioned to execute on our key priorities and reach multiple near-term value-driving events. In collaboration with our partner, Sobi, we expect to both complete the SEL-212 Phase III DISSOLVE trial and announce joint top line data in Q1 2023. We also remain on track to advance SEL-302, our proprietary gene therapy candidate in combination with ImmTOR to treat methylmalonic acidemia, or MMA, into a Phase I clinical trial in this quarter. Our key priority continues to be accelerating the development of our next-generation precision immune tolerance platform, ImmTOR-IL. We have made substantial progress in identifying a proprietary IL-2 candidate and continue to believe we'll have a clinical lead candidate by year end. Additionally, our team continues to advance our preclinical pipeline, most notably the IND-enabling studies and manufacturing scale-up for our proprietary IgG protease, Xork, as a pre-treatment for AAV gene therapies, and IgA protease candidate selection with our partners for the treatment of IgA nephropathy.